NCT06843993View on ClinicalTrials.gov

Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

MK-2060

Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization.

BIOLOGICAL

Placebo

Single doses of placebo administered via IV infusion on Day 1 according to randomization.

Trial Locations (1)

200032

Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 001), Shanghai

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY